In short
ROSE-010 is an investigational GLP-1 analogue being studied for its effects on appetite and food intake in people with overweight and obesity. One completed Phase 1 trial has tested it in 12 participants. The trial measured how much food people ate after receiving ROSE-010 compared to placebo.
Key points
- ROSE-010 is a GLP-1 analogue, a type of substance that mimics a natural gut hormone involved in appetite control.
- The only registered trial is a Phase 1 study in overweight and obesity.
- The trial enrolled 12 participants and is now completed.
- The study compared two dose levels of ROSE-010 against placebo in a cross-over design.
- The main measure was how much food was eaten at a lunch served after the injection.
- ROSE-010 was given by subcutaneous injection at a dose of 150 micrograms in the trial.
What is ROSE-010?
ROSE-010 is an investigational substance described in the trial record as a GLP-1 analogue. GLP-1 stands for glucagon-like peptide-1, a natural hormone in the body. An analogue is a substance made to be similar to that hormone. ROSE-010 has no marketing authorisation in the trial record and is still being studied in clinical research. The trial sits in the therapeutic area of nutritional and metabolic diseases.
How does ROSE-010 work?
The trial record describes ROSE-010 as a GLP-1 analogue, meaning it is designed to act like the natural hormone GLP-1. GLP-1 is involved in regulating appetite and food intake. The study measured how much food participants ate after receiving ROSE-010, which is in line with how a GLP-1 analogue might affect appetite. The available data do not give a more detailed molecular description of how ROSE-010 acts.
Which conditions is ROSE-010 studied for?
- Overweight — a condition where a person has more body fat than is considered healthy for their height.
- Obesity — a more severe form of excess body fat that can affect health.
These are the two conditions named in the completed Phase 1 trial.
How is ROSE-010 given?
In the trial, ROSE-010 was given as a subcutaneous injection, which means an injection under the skin. The dose used was 150 micrograms. The placebo was a clear colourless solution that looked the same as ROSE-010.
What do the clinical trials show?
One trial is registered for ROSE-010. It is a Phase 1 study, which is the earliest stage of testing in people, mainly looking at safety and how the body responds. The trial enrolled 12 participants and is completed. It was a randomised, placebo-controlled, double-blinded, three-treatment, three-period cross-over study. This means participants received ROSE-010 at two different dose levels and placebo at different times, without knowing which they were getting. The main outcome was the amount of food eaten during a lunch served at the clinic after administration of ROSE-010, compared with placebo.
What side effects are known?
The available sources do not report side effects for ROSE-010. The Phase 1 trial was designed to evaluate safety, but the registry record does not list specific side effects.